Is Moderna (MRNA) a Buy Right Now?
A plain-English read on Moderna stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Moderna is currently trading at $140.33. The stock is following an upward trend, as the price sits well above its 200-day average of $58.79. This 200-day average is a common tool used to see the long-term direction of a stock.
The RSI, or Relative Strength Index, is at 62.3. This is a gauge of whether a stock has climbed too far, too fast, and this level suggests there is still room before the stock is considered overbought. The price is currently moving toward its recent resistance, or ceiling, of $163.47.
Should you buy Moderna stock?
The data supports a buy signal based on the current upward momentum. However, keep in mind that the P/E ratio, a measure of price relative to earnings, is -30.9, which reflects the company's current lack of profitability. Always weigh this against your own personal risk tolerance.
Is MRNA a good stock for beginners?
Moderna can be volatile, meaning the price swings significantly, as seen in the wide 52-week range of $22.28 to $163.47. It is a large company, but beginners should be prepared for these price fluctuations. Only invest money you do not need for immediate expenses.
What's driving MRNA right now
The stock price is currently trading above its 200-day average of $58.79.
The RSI is at 62.3, showing the stock has momentum without being excessively overbought.
The company currently has a P/E ratio of -30.9, indicating it is not yet generating positive earnings.
The stock has established a recent support level, or floor, at $62.13.
What Moderna actually does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna by the numbers
Wall Street consensus on MRNA is Hold. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns Moderna?
Institutions — pension funds, asset managers, index providers — hold 80.6% of MRNA, and the concentration matters: the largest single holder alone controls 12.99% of the company.
| Holder | Shares | % held |
|---|---|---|
| 51.86M | 12.99% | |
| 30.60M | 7.66% | |
| 23.21M | 5.81% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Moderna insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Moderna, 2 were sales and 0 were open-market purchases; the other 4 were awards, vesting or option exercises rather than a decision to buy or sell. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-28 | AWARD / VEST | 1.1K | — | |
| 2026-08-28 | AWARD / VEST | 1.1K | — | |
| 2026-08-28 | AWARD / VEST | 2.0K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading MRNA?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. 7 disclosures name MRNA — filed by 4 separate members and worth $21K–$140K combined (filings report bands, never exact amounts). 1 purchase-side, 6 sale-side, most recently on 2025-04-08.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2025-04-08 | SELL | $1,001 - $15,000 | |
| 2025-02-25 | BUY | $1,001 - $15,000 | |
| 2025-01-15 | SELL | $1,001 - $15,000 |
Names withheld — plus 4 more records not shown.
See which membersWith the price holding above key averages and momentum building, the data points to a buy, though caution regarding profitability is warranted.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice MRNA risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about MRNA
Should I buy MRNA stock?+
The current data indicates a buy signal as the price of $140.33 remains above its 200-day average.
Is MRNA a good long-term investment?+
While the trend is currently up, the negative P/E ratio of -30.9 shows the company is not yet profitable, which is a factor for long-term holders.
Is MRNA a buy or a sell?+
Based on the technical momentum and the price sitting above the 200-day average, the data currently supports a buy.
Is MRNA overvalued?+
The stock is trading at $140.33, which is below its 52-week high of $163.47, but the negative P/E ratio makes traditional valuation difficult.
Is MRNA a good stock for beginners?+
Beginners should be aware of the high volatility, as the stock has moved between $22.28 and $163.47 over the last year.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Moderna (MRNA) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-09-08 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.